Every day an increasing number of patients with Tyrosinemia Type 1 in the US trust NITYR as their nitisinone medication of choice. NITYR can fit into your life with the convenience, discretion, and flexibility you need.
Information for Patients
100% of fully enrolled, insured patients with HT-1 who have received NITYR have not voluntarily returned to Orfadin*1
NITYR is bioequivalent to Orfadin* (nitisinone) capsules, which means that it has the:
- Same efficacy
- Same safety
- Same side effects, and may offer greater convenience2
Try. Compare. Decide.
You have the opportunity to try the NITYR Experience, compare it to your current nitisinone medication and decide if it is right for you. With the 30-Day Free NITYR Program*, there’s:
- no financial obligation
- no commitment
- no impact on your current nitisinone supply
Connect with Patient Liaison Support anytime you have a question or concern. Call 1-800-847-8714.
* Orfadin is a registered trademark, licensed by Swedish Orphan Biovitrum AB (publ) and is marketed by Sobi, Inc.
**30-Day Free NITYR Program: Patients can try NITYR for 30 days, one time, for free, as long as their doctor prescribes it. Subject to terms and conditions, eligibility criteria, and other federal and state law. Terms and Conditions and eligibility criteria are available at www.nityr.us/offertcs
References: 1. Data on file: NIT/03/21. Data represents fully enrolled, insured NITYR patients in the US from August 2017 to February 2021. 2. Data on file: NIT/02/20.